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Most mutations in cancer genomes are thought to be
acquired after the initiating event, which may cause
genomic instability and drive clonal evolution.
However, for acute myeloid leukemia (AML), normal
karyotypes are common, and genomic instability is
unusual. To better understand clonal evolution in
AML, we sequenced the genomes of M3-AML
samples with a known initiating event (PML-RARA)
versus the genomes of normal karyotype M1-AML
samples and the exomes of hematopoietic stem/
progenitor cells (HSPCs) from healthy people.
Collectively, the data suggest that most of the muta-
tions found in AML genomes are actually random
events that occurred in HSPCs before they acquired
the initiating mutation; the mutational history of that
cell is ‘‘captured’’ as the clone expands. In many
cases, only one or two additional, cooperating muta-
tions are needed to generate the malignant founding
clone. Cells from the founding clone can acquire
additional cooperating mutations, yielding sub-
clones that can contribute to disease progression
and/or relapse.
INTRODUCTION
The molecular pathogenesis of acute myeloid leukemia (AML)
has not yet been completely defined. Recurrent chromosomal264 Cell 150, 264–278, July 20, 2012 ª2012 Elsevier Inc.structural variations (e.g., t(15;17), t(8;21), inv(16), t(9;21),
t(9;11), del5, del7, etc.) are established diagnostic and prog-
nostic markers, suggesting that acquired genetic abnormalities
play an essential role in leukemogenesis (Betz and Hess,
2010). However, nearly 50% of AML cases have a normal karyo-
type (NK), and many of these lack recurrent structural abnormal-
ities, even with high density comparative genomic hybridization
(CGH) or SNP arrays (Bullinger et al., 2010; Suela et al., 2007;
Walter et al., 2009). Targeted sequencing efforts have identified
several mutations that carry diagnostic and prognostic informa-
tion, including mutations in FLT3, NPM1, KIT, CEBPA, and TET2
(reviewed in (Bacher et al., 2010; Stirewalt and Radich, 2003)).
The advent of massively parallel sequencing enabled the
discovery of recurrent mutations in DNMT3A (Ley et al., 2010;
Yamashita et al., 2010) and IDH1 (Mardis et al., 2009). Despite
these efforts, more than 25%of AML patients carry nomutations
in the known leukemia-associated genes (Shen et al., 2011).
Furthermore, defining the molecular consequences of recurring
mutations (e.g., whether a mutation is an initiating or a cooperat-
ing event) has been challenging.
PML-RARA is one of the best-characterized leukemia-initi-
ating mutations. This fusion gene results from t(15;17)(q22;21)
and is associated exclusively with acute promyelocytic leukemia
(APL, FAB M3 AML) (Allford et al., 1999; Rowley et al., 1977). Its
expression is diagnostic of this single type of leukemia with
unique clinical features (Sanz et al., 2009). Its presence predicts
a near universal therapeutic response to a targeted agent, all-
trans retinoic acid (ATRA), which is abrogated by mutations
that inhibit ATRA binding to PML-RARA (Imaizumi et al., 1998;
Larson and Le Beau, 2011; Takayama et al., 2001). Early myeloid
expression of PML-RARA results in leukemia with promyelocytic
features in multiple mouse models of the disease, although long
latency (which can be shortened by radiation, alkylator treat-
ment, or FLT3 ITD coexpression), suggests that PML-RARA
requires cooperating events to cause leukemia (Funk et al.,
2008; Kelly et al., 2002; Kogan, 2007; Sohal et al., 2003; Walter
et al., 2004).
In this study, we sequenced the genomes of 24 AML cases.
We chose to compare 12 genomes from patients with FAB M3
AML (where the initiating event is known) to 12 genomes from
patients with AML without maturation (FAB M1) with normal
cytogenetics, where the initiating event is less clear for most
patients. In this and previous studies, we have demonstrated
that AML genomes generally contain hundreds of mutations,
that the total number of mutations per AML genome is related
to the age of the patient, and that nearly all AML cells in the
samples contain all of the mutations (although very few of these
mutations are recurrent in AML or other malignancies) (Ding
et al., 2012; Ley et al., 2008; Link et al., 2011; Mardis et al.,
2009; Welch et al., 2011b). We show here that clonally derived
hematopoietic cells from normal individuals also accumulate
mutations as a function of age. This suggests that most of the
mutations present in AML genomes were already present in
the hematopoietic cell that was "transformed" by the initiating
mutation; nearly all of these preexisting mutations are probably
benign and irrelevant for pathogenesis.
Consistent with this hypothesis, we observed that M1 and M3
genomes have similar numbers of total mutations and that M1
genomes contain unique mutations (e.g., DNMT3A, NPM1,
IDH1, or TET2) that almost never occur in M3 cases. In addition,
there are many mutations that are shared between the two
subtypes (e.g., FLT3 ITD), suggesting that these mutations can
cooperate with a variety of initiating mutations. Because the
data are comprehensive for all 24 genomes, it also allows us to
estimate the minimum number of recurring mutations that may
be responsible for the pathogenesis of AML.
RESULTS
Whole-Genome Sequencing of 24 AML Samples
We subjected 12 cases of NK M1 AML and 12 cases of t(15;17)-
positive M3 AML to whole-genome sequencing (WGS) (case
descriptions provided in Extended Experimental Procedures,
summarized in Table S1 and Figure S1 available online). To iden-
tify somatic, AML-associated mutations, we subjected both the
bone marrow (leukemic tissue) and skin (normal tissue) to WGS
(average haploid coverage 28x, Figure 1A and Table S2); the
mutations in the AML1 andAML2 genomes have been previously
reported and deposited in dbGaP (Ding et al., 2012; Ley et al.,
2008; Mardis et al., 2009). They are included in this study for
ease of reference. Because of the prevalence of false-positive
calls in WGS (between 20%–50%, depending on the stringency
of type I errors tolerated), we validated all single nucleotide vari-
ants (SNVs), small insertions and deletions (indels), and struc-
tural variants (SVs) identified in tiers 1, 2, or 3 (which contain
the nonrepetitive portion of the genome (see Mardis et al.,
2009 for definitions of tiers) by using patient-specific custom
NimbleGen capture arrays, followed by Illumina sequencing (Fig-
ure 1B). All subsequent analysis relies on these validated dataand not on the primary genome discovery sequence. An average
coverage of 972 reads per somatic variant was obtained at
validation. We observed a higher validation frequency in tier 1
than in tier 2 and 3 (mean frequency 0.5 versus 0.35 and 0.29,
p < 0.002 and p < 0.0001, respectively; Table S2), which may
reflect the lower guanine and cytosine content and increased
uniqueness of tier 1. Numbers of mutations and validation
frequencies were similar across all tiers in M1 versus M3
genomes (Figures 1C–1E and Table S2). These data yielded
a total of 10,563 validated somatic variants for the 24 genomes
(average 440/genome) (Tables S2, S3, and S4). Indels were
less frequent than SNVs in M1 and M3 AML (M1: average 19.1
per genome, range 4–45; M3: average 20.3 per genome, range
4–56), and occurred proportionally less often in tier 1 (average
1.4 per genome, range 0–4). Of these total somatic mutations,
319 occurred in the coding regions of 287 unique genes; an
average of 10 somatic mutations had translational conse-
quences in each genome (Table S3). A fusion event between
PML and RARA was identified in all 12 M3 AML cases (Table
S5). Only 43 additional structural variants (translocations, inser-
tions, deletions, and inversions) were identified (median 2 per
genome, range 0–8, Table S5). The t(15;17) breakpoints
occurred in exon 5 and introns 3 and 5 of PML and within
RARA intron 2 in all cases, as expected; two cases were associ-
ated with large deletions that are predicted to result in PML-
RARA expression without reciprocal RARA-PML expression
(Figure S2). None of the other structural variations found by
WGS were identified with metaphase cytogenetics; most are
predicted to be cryptic when examined by routine cytogenetics.
The others may exist in minor leukemic subclones that were not
otherwise detected, or in cells that did not expand during prep-
aration for cytogenetic studies.
The total number of validated SNVs per genome increased in
proportion to patient age, in bothM1 andM3 AML genomes (Fig-
ure 1F). We also observed that somatic AML mutations were
widely distributed throughout the genome; in all 24 cases, the
number of SNVs in each tier was directly proportional to the
amount of the genome present in that tier (SNVs per Mb: tier 1:
0.264 ± 0.024; tier 2: 0.283 ± 0.026; tier 3: 0.283 ± 0.024, p <
0.91) (Figure 2A) and these mutations were distributed across
all chromosomes (Figure 2B). However, with this sample size,
modestly increased mutational frequency within small regions
of the genome cannot be excluded (Figures 2C and 2D).
The mutational spectrum was dominated by C>T/A>G transi-
tions, and was similar for M1 and M3 cases (Figure 2E). Tier 1
mutations favored C>T/A>G transitions, probably due to an
increased proportion of methylated cytosine nucleotides in tier
1, which is associated with increased susceptibility to deamina-
tion and subsequent transition mutations (Figure 2F) (Pfeifer,
2006).
For this study, skin samples were obtained when the patients
presented with leukemia. As expected, we observed low-level
contamination of leukemic variants in the skin samples, which
was proportional to the peripheral white blood cell (WBC) count
at the time of skin collection (Figures S3A–S3C). M3 AML
cases usually had very low leukemia contamination in the skin
(often completely absent), although we observed two outlier
cases. There was no correlation between disproportionallyCell 150, 264–278, July 20, 2012 ª2012 Elsevier Inc. 265
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Figure 1. Coverage and Number of Validated SNVs by Tier per Genome
(A) Gigabase pairs of sequence obtained for each genome assessed by whole-genome sequencing.
(B) Mean number of reads obtained for each variant assessed per genome during validation.
(C and D) Number of tier 1, 2, 3, and total variants validated in each sample.
(E) Total number of validated SNVs by tier in M1 AML (red) versus M3 AML (blue) cases.
(F) Total number of validated SNVs per genome in nonredundant regions (tier 1, 2, and 3) versus age of patient; M1 AML (red), M3 AML (blue). The R2 for the
combined 24 cases is 0.5, p < 0.0001.
See also Figures S1 and S2 and Tables S1–S4.
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D
B Figure 2. Genomic Distribution of Somatic
Variants
(A) Percentage of validated SNVs in each tier
versus the number of genomic megabases occu-
pied by that tier; M1 (red), M3 (blue). Average R2
M1: 0.999 (range: 0.998–1.000); M3: 0.999 (range:
0.998–1.000).
(B) Distribution of validated SNVs throughout the
genome. Each point represents the genomic
position of an SNV: x axis represents chromo-
somes in numerical order; y axis represents base
pair position on each chromosome in megabase
pairs; M1 AML (red), M3 AML (blue). The large
discontinuous regions represent regions of the
reference genome without defined sequence.
(C) Average (circle), standard deviation (bars), and
maximal (triangles) number of SNVs permegabase
by chromosome in all 24 cases.
(D) Frequency of SNVs per megabase of non-tier 4
genomic space compared with the expected
Poisson distribution if SNVs were randomly
distributed across non-tier 4 space.
(E) Mutational spectrum of validated SNVs.
Percentage of validated SNVs that occur in
nonredundant regions of the genome (tiers 1, 2,
and 3) with indicated nucleotide changes in M1
AML (red) and M3 AML (blue).
(F) Mutational spectrum as defined by tier of each
event (tier 1, genic; tier 2, highly conserved and/or
with regulatory potential; tier 3, unique in the
genome, and not in tier 1 or tier 2, see Mardis et.al.
2009 for details).high skin contamination and clinical history (e.g., leukemia
cutis, gum hypertrophy, pulmonary hemorrhage, or intracranial
hemorrhage).
Clusters of mutations with similar variant allele frequencies
within individual cases provide evidence of a single founding
clone in bothM1 andM3 samples (Ding et al., 2012). Using kernel
density analysis, we identified one to four clusters of mutations
(representing the founding clone in all cases, with or without
additional subclones derived from the founding clone) in each
genome (Figures 3A–3D); the clusters were independent of the
number of read counts for each SNV. In cases with subclones,
the number of variants specific to each subclone was relatively
small (an average of 40.4 SNVs per subclone [range 6–110]);
SNVs in subclones represented only 14% of the total SNVs per
genome (range 2%–33%). Because each genome’s founding
clone contains heterozygous SNVs that appear to be present
in nearly all of the cells in the sample, subclones must also
contain all of the SNVs in the founding clone. For example, the
average variant frequency of heterozygous SNVs in the foundingCell 150, 264–clone of AML13 (Figure 3D) is 44%, sug-
gesting that 88% of the cells in the
sample contain these heterozygous
mutations; therefore, the subclones with
average variant allele frequencies of
12%, 22%, and 32% must also contain
the mutations found in the founding
clone. Genomes with two or more muta-tion clusters displayed a similar standard deviation of variant
frequencies within separate clusters (Figure 3E). However,
genomes with a single cluster tended to have an increased stan-
dard deviation of the variant frequency within that cluster, sug-
gesting that overlapping subclones may exist in these samples
that are below this level of resolution. There was a trend toward
more subclones in M3 cases (M1 average, 1.5 clones/genome;
M3 average, 2.2 clones/genome; p = 0.04) (Figure 3F).
Several pieces of data suggest that most of the mutations
in the founding clone may be random events that preexisted in
the hematopoietic cell that acquired the initiating mutation: (1)
the presence of hundreds of mutations in the founding clones
of all AML genomes (which is far greater than the number ex-
pected to be biologically relevant), (2) their presence in nearly
all of the AML cells in the sample, and (3) the correlation
of the number of total mutations with the patient’s age. We
expect that an AML-initiating mutation would provide a growth
advantage for an HSPC and that the preexisting, random muta-
tions in that HSPC would therefore be ‘‘captured’’ in all its278, July 20, 2012 ª2012 Elsevier Inc. 267
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progeny when that cell clonally expands. Even though the preex-
isting mutations would not be pathogenetically relevant, they
would be present in all of the cells in the founding clone, and
appear as somatic mutations when the AML sample is
sequenced. Although this hypothesis cannot be proven directly
with current technologies, it strongly suggests that HSPCs
derived from healthy people may acquire random, benign muta-
tions as a function of age. This issue is addressed in the next
section.
Identification of Background Mutations in Normal
Human Hematopoietic Cells
To determine whether normal human hematopoietic cells accu-
mulate mutations over time, we performed exome sequencing
on the progeny of three different HSPCs from seven healthy indi-
viduals of different ages, and compared these sequences to
those of normal peripheral blood from the same donors (which
are thought to have contributions from 1,000 hematopoietic
stem cells at any given time) (Abkowitz et al., 1996; Abkowitz
et al., 2000; Catlin et al., 2011). Details of the experiments are
provided in Experimental Procedures and Figure S6.We focused
on mutations with variant allele frequencies of 50% (±2 SDs),
which strongly suggests that they are present in all cells in the
sample; mutations that are not present in all cells may have
arisen during the outgrowth of the HSPCs in culture and would
be artifacts of the ex vivo expansion. The number of validated
mutations in each clonally derived sample was lowest in the
cord blood samples and increased as a function of age (Fig-
ure 4A); in adult volunteers, the number of mutations detected
in each exome was similar to that detected in AML patients of
the same age. Each of the mutations was distinct for each of
the clones (Figure 4B and Table S6). The mutational spectrum
was very similar to that of AML samples (Figure 4C); both have
mostly transitions, suggesting that theymay representmutations
caused by deamination of methylcytosine residues. Collectively,
these data suggest that normal, self-renewing hematopoietic
stem cells accumulate random background mutations as a func-
tion of age. These background mutations would therefore be
present in all cells present in an AML founding clone, would
increase with age, and would generally be irrelevant for AML
pathogenesis.
Identification of Genes with Recurring Mutations
To better identify the recurrently mutated genes in the
sequenced AML genomes, we extended the analysis to addi-
tional AML cases. A liquid-phase capture approach followed
by Illumina sequencing was used to assess themutational status
of 284 of the tier 1 mutated genes in an additional 53 M1 and 31
M3 cases (Figure S1D and Table S7). We also assessed theFigure 3. Clonality Assessment in NK M1 AML and t(15;17)-Positive M
(A–D) Clusters of variants that occur with similar frequencies identify AML founding
density estimation of data in lower panels. The graphed line shows the relative pr
each SNV, the frequency of the variant allele within the bone marrow sample is pl
nucleotide position. Triangles indicate SNVs on the X chromosome.
(E) The standard deviation of the variant frequency for each cluster in all 24 cases:
estimation in M1 AML (red) and M3 AML (blue).
See also Figures S3, S4, and S5.mutational status of 53 genes previously reported to be mutated
in AML (see Extended Experimental Procedures). Forty-one of
these cases did not have a matched normal sample.
Among the 108 genomes assessed, we identified 23 genes
containing mutations with translational consequences in at least
3 independent samples (Figure 5A). In the 24 cases subjected to
WGS, we observed an average of 14.5 tier 1 mutations per
genome (M1: 14.8 ± 1.9; M3: 13.3 ± 1.4; p = 0.5, Figure 5B). Of
those, there was an average of 3 recurrent mutations in each
M1 genome (3.4 ± 0.7, range 0–7) versus 2 recurrent mutations
in each M3 genome (2.2 ± 0.3, range 1–5, p = 0.1, including
PML-RARA, Figure 5C). Among the 108 total genomes as-
sessed, there were an average of 2 recurrently mutated genes
per M1 sample (M1: 2.2 ± 0.2, range 0–10) versus 2 genes per
M3 sample (1.7 ± 0.1, range 1–4; p < 0.09, including PML-RARA,
Figure 5D).
Patterns of Recurrent Mutations in M1 versus M3 AML
Genomes
We identified nine recurrently mutated genes found in both the
M1 and M3 genomes (FLT3, TTN, NRAS, PKD1L2, CACNA1E,
DNAH9, WT1, ANKRD24, and PHF6) (Figure 5A). Mutations in
these genes may represent cooperating events that are capable
of interacting with several different initiating mutations.
Thirteen genes were recurrently mutated only in M1 genomes
(NPM1, DNMT3A, IDH1, TET2, IDH2, RUNX1, ASXL1, PTPN11,
DIS3, KIT, SMC1A, SMC3, and STAG2) (Figure 5A), suggesting
that they might be involved with AML initiation. Of this group,
six had mutation frequencies that were statistically higher in
M1 versus M3 patients (NPM1, p < 0.0001; IDH1, p < 0.0001;
IDH2, p < 0.01; TET2, p < 0.001; DNMT3A, p < 0.0001; ASXL1,
p < 0.03).
Mutations in three genes (NPM1, DNMT3A, and IDH1) coex-
isted only in M1 genomes. These genomes contained additional
mutations that were also found in M3 genomes. Recurring muta-
tions that co-occur with PML-RARA are likely to be cooperating
mutations, rather than initiating mutations. This further suggests
thatmutations inNPM1,DNMT3A, and IDH1, aremore likely to be
initiating, rather than cooperating, events in M1 AML genomes.
We observed nonrandom associations of NPM1, DNMT3A,
IDH1, and FLT3 mutations in M1 AML cases, as follows:
NPM1+DNMT3A, p < 0.028; NPM1+IDH1, p < 0.011; NPM1+
FLT3, p < 0.014; DNMT3A+IDH1, p < 0.001; DNMT3A+FLT3,
p < 0.04, similar to our previous report and to others (Figure S7)
(Ley et al., 2010; Markova´ et al., 2012; Shen et al., 2011).
We extended these findings by examining mutational
frequency data from whole-genome or exome sequencing
studies of 131 additional AML cases that included all other FAB
subtypes from the TCGA AML study (Figure 5A and Table S3).3 AML
clones and subclones. Upper panels: probability density function using kernel
obability of each variant allele frequency in the total sample. Lower panels: for
otted versus the total number of sequencing reads covering the corresponding
M1 AML (red); M3 AML (blue). F. Number of clusters identified by kernel density
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(A) Number of validated SNVs per exome identified in each of 3 clones that were derived from individual hematopoietic stem/progenitor cells from 7 anonymous,
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Figure 5. Recurrently Mutated Genes in M1 and M3 AML
(A) 108 total cases ofM1 andM3AMLwere screened for somatic variants in the 284 genes identified byWGS and in 53 genes previously reported to bemutated in
AML. Mutations with translational consequences that occur in at least three unique genomes are represented in red. FAB subtype indicated above graph. Overall
survival is indicated by red (%12 months), pink (12–24 months), and white (>24 months) bars above graph.
(B) The total number of validated genic variants per genome identified by WGS in 12 NKM1 AML cases (red) and 12 M3 AML cases (blue), including PML-RARA.
(C) The total number of recurrently mutated genes per genome identified in 12 NK M1 AML cases (red) and 12 M3 AML cases (blue), including PML-RARA. Only
mutations with translational consequences were assessed.
(D) Total number of recurrentlymutated genes per genome identified in 65M1 AML cases (red) and 43M3AML cases (blue), includingPML-RARA. Onlymutations
with translational consequences were assessed.
(E) Somatic variants in cohesin complex genes (SMC3, SMC1A, STAG2, and RAD21) identified in 199 cases of AML (red). Additional mutations with translational
consequences in highly recurrent genes are also shown for each genome (red).
See also Figures S7 and S8 and Table S7.Most of the genes (20/23) were recurrently mutated in these
additional samples, suggesting that these mutations may partic-
ipate in the pathogenesis of other AML subtypes, as expected.
Some genes with low mutation frequencies in the M1 and M3
cases were not recurrently mutated in the 131 additional cases
(e.g., ANKRD24, DIS3, and PML-RARA), but none of the differ-
ences were statistically significant.
Three of the recurrently mutated genes, STAG2, SMC3, and
SMC1A, are members of the cohesin complex, which is a tetra-(B) Clustering of mutations by clone. The y axis represents the analyzed clones f
(red). Note that the two clones with ZFHX4 variants contained unique mutations
(C) Mutational spectrum in normal donor exomes (81 validated variants) versus 2
See also Figure S6 and Table S6.meric structure that also includes RAD21; this complex is
involved in sister chromatid separation during anaphase, and
CTCF-mediated chromatin topologic constraints (Carretero
et al., 2010; Millau and Gaudreau, 2011). STAG2 was recently
found to be deleted in an AML genome (Walter et al., 2009)
and in cancer cell lines (Rocquain et al., 2010; Solomon
et al., 2011). We therefore assessed all four genes for mutations
in a larger set of 183 AML samples subjected to exome or
whole-genome sequencing as a part of The Cancer Genomerom each donor. The x axis represents the genes with mutations in each clone
(Q1660K versus P3497A).
4 tier 1 AML genomes (343 validated variants).
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Atlas (TCGA) study of AML (T.J.L., and R.K.W., unpublished
data). We identified mutations in all four cohesin complex genes,
whereas the related genes STAG1 and STAG3were not mutated
(Figure 5E). These mutations were not detected in any M3
genomes. Of the 19 mutations identified in cohesin complex
genes, 11 had loss-of-function consequences (nonsense, splice
site, or gene deletions). Two cohesin complex genes are found
on the X chromosome, and mutations in those genes were iden-
tified in six male patients. Cohesin complex genemutations were
not associated with chromosomal instability (Solomon et al.,
2011); 12 of the cases with cohesin mutations had normal cyto-
genetics, six had three or fewer cytogenetic abnormalities, and
only one had complex cytogenetics.
We examined the expression of all of the recurrently mutated
genes by using expression array data for all of the M1 and M3
cases available in our data set (Figure 5A and Table S3). The
expression values of all probe sets on these arrays are normal-
ized to an average chip mean of 1,500. Most of the recurrently
mutated genes are highly expressed in both M1 and M3 AML
cases. Several of the genes had very low expression levels
(e.g., TTN, PKD1L2, ANKRD24, CACNA1E, and DNAH9) on the
Affymetrix U133 Plus 2 array. Using readcounts from RNA-Seq
data obtained from 155 AML cases from the TCGA study of
AML, we were able to show that spliced transcripts from TTN
and ANKRD24 are detected in virtually all AML samples tested,
whereas PKD1L2, CACNA1E, and DNAH9 transcripts were
absent in all (or nearly all) of the same samples. We suggest
that mutations in genes that are not detectably expressed are
less likely to be relevant for pathogenesis.
We identified only two germline variants that were likely to be
relevant for AML pathogenesis: WT1 R430* in AML15 (age 25),
and PTPN11 Y197* in AML9 (age 25). These data are presented
in the Extended Experimental Procedures and Table S8.
Integration of Coexisting Variants within Individual
Patients
Mutations that may be relevant for AML pathogenesis are inte-
grated for all 24 fully sequenced patients in Table 1. This analysis
identified at least two likely AML driver mutations (in genes that
are recurrently mutated in AML and/or other cancer types and
expressed in the patient’s own AML sample) in 23 of 24 cases
and at least 4 likely drivers in 15 of 24 cases. This outcome is
consistent with our predicted statistical power from this experi-
mental design and sample size (see Extended Experimental
Procedures). These mutations are organized into currently
annotated pathways (Figure 6), which reveal potential relation-
ships among genes that are infrequently mutated in this set of
cases.
DISCUSSION
In this report, we describe the comprehensive sequencing of the
entire genome of 24 carefully selected acute myeloid leukemia
cases. Paired-end sequencing of the entire tumor and normal
skin genomes was performed for each case, along with indepen-
dent validation of all putative mutations identified in the nonrep-
etitive part of the human genome. We compared the genomes of
patients with a known initiating mutation (PML-RARA) with272 Cell 150, 264–278, July 20, 2012 ª2012 Elsevier Inc.genomes that have less known about the initiating events (AML
without maturation-FAB M1 with normal karyotype). Both AML
subtypes have approximately the same number of overall muta-
tions in their genomes, and both are associated with relative
genomic stability (in all cases we observed a small number of
total SNVs, indels, and SVs, compared with most solid tumors).
The SNVs were distributed across the entire genome, and the
mutational spectrum of SNVs was virtually identical between
the two AML subtypes. By comparing these two subtypes of
AML, we were able to distinguish the mutations that are likely
to be initiating events in the cytogenetically normal cases, versus
the cooperating events that are common to both subtypes; this
analysis suggests that mutations in NPM1, DNMT3A, and IDH1
may act as major initiating mutations in M1 AML.
We found a small number of mutations with translational
consequences (e.g., nonsynonymous mutations in tier 1) in
each of the 24 genomes: the average was 11 for M1 AML
and 10 for M3 AML (including the PML-RARA fusion event).
Only a portion of these mutations were found to be expressed
in the patient’s sample and recurrent in other M1/M3 AML
genomes, yielding amedian number of three recurringmutations
in M1 genomes, versus two in M3 genomes (including the PML-
RARA fusion). Additional mutations are likely to contribute to
pathogenesis (such asmutations that occur with <3% frequency
in AML or that occur in solid tumor-associated genes), although
their biological significance in AML is less certain (Table 1 and
Figure 6).
These data, because they were derived from completely
sequenced genomes, allow us to estimate the minimum number
of genic mutations that may be required for AML pathogenesis.
We observed one M3 AML genome in which the only detected
recurrent AML or cancer-associated tier 1 somatic mutations
were PML-RARA and FLT3 ITD (AML9; Table 1 and Figure 6).
In mice, this combination of mutations can cooperate to accel-
erate the onset (or development) of AML with many of the
features of acute promyelocytic leukemia (Kelly et al., 2002;
Sohal et al., 2003). Furthermore, by sequencing an APL
genome-derived from a mouse expressing human PML-RARA,
we recently defined a recurring, spontaneous mutation in the
Jak1 gene at position V657F (Wartman et al., 2011); this mutation
that is identical to that found in some human patients with B
lymphoblastic leukemia (Flex et al., 2008; Harvey et al., 2010;
Mullighan et al., 2009) and a patient with M3 AML (Jeong et al.,
2008). When this Jak1 mutation was coexpressed with PML-
RARA in mice, the animals developed an explosive, oligoclonal
APL syndrome within 4 weeks, strongly suggesting that these
two mutations were sufficient to produce the disease (Wartman
et al., 2011). These data support the idea that as few as two key
somatic mutations may cause AML in some patients.
We observed that human hematopoietic stem/progenitor
cells (HSPCs) from healthy volunteers each contain private
mutations that accumulate as a function of age; we calculated
that 0.13 ± 0.02 exonic mutations are acquired per year of life
(Figure 4A). Current models of human hematopoietic stem cells
(HSCs) suggest that one cell division occurs every 25–50 weeks
(Catlin et al., 2011). Experimental methods of interrogating
human HSC turnover are, however, somewhat limited. Murine
HSC division rates are better characterized, and the data
Table 1. Patient-Specific Mutations that May Contribute to AML Pathogenesis
UPN
WGS
Number FAB
Age
at Dx
Structural
Variants1 Clones
OS
(Months)
Mutated in AML, 2
Expressed in Patient3
Mutated in AML,2 Not
Expressed in Patient4
Mutated in Other
Cancer Types,5
Expressed in Patient3
Inherited Mutation
in AML Gene,
Expressed in Patient3
933124 AML1 M1 57 3 1 24.6 NPM1, FLT3, SMC3, DNMT3A,
GPR183, TTN
PCDH24, SLC15A1, PTPRT,
GPR123
PDXDC1, PRKRA6
807970 AML2 M1 38 0 2 54.9 NPM1, IDH1, NRAS, CEP170,
C19orf62
FREM2
123172 AML3 M1 56 0 2 53.9 NPM1, FLT3, SMC1A,
PTPN11, ZFHX3, UNC5B
EPHA8, EGFL8 BMS1, RFC1
831711 AML4 M1 57 0 1 53.4 STAG2, TET2 MUC5B, CACNA1E CAMTA1, ARHGAP5
849660 AML5 M1 22 5 1 27 KAT2B
808642 AML6 M1 61 5 2 15.5 FLT3, TET2 ZNF687, MAP1B, TRPC1 DDR2, ATP9B, USP44
509754 AML7 M1 21 8 2 73.9 NPM1, IDH1 TRPM4, WNK4
327733 AML8 M1 32 3 2 56.3 NPM1, IDH1, SLC24A3, MPND
224143 AML21 M1 67 1 1 0.8 NPM1, FLT3, DNMT3A MYH14, MUC5B, MUC5B, ABCA10
545259 AML33 M1 30 0 1 33.7 CEBPA GBP4 TRIM24
548327 AML34 M1 51 2 2 31.9 NPM1, IDH1 LAMA5, EPB41L5, ANKRD24 SOS1
804168 AML40 M1 53 1 1 30 NPM1, FLT3, WT1, PHF6,
LRRC37B
SDK2, SRCRB4D, FAM5C,
LBXCOR1, OR4C15
MED14, DAGLB
709968 AML9 M3 25 2 2 71.7 PML-RARA,6 FLT3 ODZ2 PTPN11 Y197*
863018 AML10 M3 62 4 2 69.4 PML-RARA,6 UNC5B,
COL11A2, ABL1
GDPD4 SHQ1, DDR2, MLC16
478908 AML11 M3 50 1 2 35.5 PML-RARA,6 FLT3, RBKS DCT CACNA2D3
344551 AML12 M3 48 3 1 69.3 PML-RARA,6 WT1, NAV1, NOS1 C1orf168 TTLL5, PAPPA2, BICD1
673778 AML13 M3 53 3 4 76.1 PML-RARA,6 ETV6, SRRM2 TOP3B EWSR1, MLL3-BAG26
321258 AML14 M3 31 1 3 64.3 PML-RARA,6 WAC, HIVEP1,
C5orf25
CACNA1E, SI AFF2, USP9X, RUFY1,
PRPF8
758168 AML15 M3 25 5 1 49.8 PML-RARA,6 AKAP13, DIS3 DNAH9, CNTN5, MUC5B CUL3, CELSR1 WT1 R430*7
455499 AML16 M3 29 3 2 37.1 PML-RARA6 OVGP1
202127 AML48 M3 68 1 1 1 PML-RARA,6 FLT3, HERC1 PKD1L2, FAM5C
529205 AML49 M3 59 2 2 31.3 PML-RARA,6 FLT3 EPHB1, LOC100133292 AURKB, IKZF1, PTPRG
501944 AML50 M3 40 1 3 73.6 PML-RARA6 KRTAP26-1, ZNF788 MYCBP2, MAX, VCAM1,
ARID2, KIDINS220, CNOT3
943309 AML51 M3 35 1 3 63.1 PML-RARA,6 FLT3 DCTN1
1Details regarding structural variants in Table S5.
2At least 4 separate cases of AML with somatic mutations in this gene within 222 cases analyzed.
3Gene expressionR800 by Affymetrix U133 Plus2 array (chip mean 1,500).
4Gene expression <800 by Affymetrix U133 Plus2 array (chip mean 1,500).
5At least four separate cases with somatic mutations in this gene in Cosmic databases.
6Structural variant.
7Absent in ESP cohort (N = 4540).
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Figure 6. Pathway Analysis of Key Mutations in the 24 Sequenced
Genomes
Mutations identified in Table 1 were individually curated in Pubmed for bio-
logical function. Functional categories represented by 2 or fewer mutated
genes were excluded. Mutations in NPM1, DNA methylation, and cohesin
genes occurred only in the M1 cases, suggesting that they may substitute for
PML-RARA as initiating events, or do not productively cooperate with PML-
RARA. Mutations in ubiquitin pathway genes occurred more often in M3 AML.
Genes representing other functional categories were mutated in both M1 and
M3 AML cases.
274 Cell 150, 264–278, July 20, 2012 ª2012 Elsevier Inc.suggest that murine HSCs fluidly transition between two pools,
one cycling every 2–6 weeks and a second cycling every 20–
50 weeks (Foudi et al., 2009; Takizawa et al., 2011). DNA replica-
tion fidelity rates have beenmeasured between 0.06–1.53 109,
depending on cell type (germ cells have the highest fidelity, and
cells grown in tissue culture have the lowest) (Gundry and Vijg,
2012; Lynch, 2010). Therefore, if HSPCs have a fidelity rate of
0.78 3 109 mutations per genomic base pair per cell division
(midway between the fidelity of germ cells and cells in tissue
culture), and undergo 2–20 divisions per year, we would predict
that they would acquire between 0.069–0.858 exonic mutations
per year. The mutation rate we have measured is within the ex-
pected parameters, which are based on our current under-
standing of replication fidelity and HSPC cell division rates.
These data provide a plausible explanation for the large number
of unique background mutations in each AML genome.
These data are consistent with previously describedmodels of
oncogenesis (Figure 7) (Armitage and Doll, 1957; Calabrese
et al., 2004; Loeb et al., 1974; Nowell, 1976; Tomlinson et al.,
1996). In the first step of leukemogenesis, a driver mutation
(e.g., PML-RARA or NPM1) occurs within the context of an
HSPC that already contains hundreds of random, benign muta-
tions that have accumulated over time. This mutation confers an
advantage to this cell, and as a consequence, all of the random
background mutations within its genome (passengers) are
‘‘captured’’ and are carried forward as the clone expands.
When an additional driver mutation (e.g., FLT3 ITD) occurs within
a cell in an expanding clone, any additional passenger mutations
that have accumulated in that cell (since acquisition of the first
driver mutation) also will be captured. Eventually, these cells
become the ‘‘founding’’ clone that is detected at presentation,
which contains only a few drivers, but many passengers that
were captured at initiation and a few additional passengers
that were captured as cooperating events were added. Each
progression event (and/or events that contribute to subclone
outgrowth) probably yields a small cluster of new mutations, of
which only one or two may be relevant for clonal outgrowth.
Our data suggest that the number of additional passengers
added with progression events is typically much smaller than
the number of passengers captured with the initiating event
(which accumulated over the lifetime of the founding cell).
The 13 recurrently mutated genes that are found only in M1
samples may be involved in the initiation of M1 AML. Mutations
in NPM1, DNMT3A, and IDH1 occur only rarely in M3 genomes
(Ley et al., 2010; Lin et al., 2011; Shen et al., 2011), and co-occur
more often than can be explained by chance (Ley et al., 2010;
Markova´ et al., 2012; Shen et al., 2011). This pattern suggests
that mutations in these genes may sometimes cooperate to
initiate AML and that this is likely to be a central AML pathway,
around which rare and private mutations can coalesce. No
patterns of cooperation could be discerned between the other
recurrentlymutated genes that areM1-specific, except formuta-
tions in the genes that encodemembers of the cohesin complex,
which will be discussed below.
Nine recurrently mutated genes were detected both in M1 and
M3 genomes, suggesting that these mutations may cooperate
with a variety of initiating events to produce the disease. By far
the most frequently mutated gene in this set is FLT3, where
X X + 1
M1 initiating mutations
(NPM1, DNM3A, IDH1, TET2 & others)
M3 initiating mutation
HSPC founding AML
clone
subclone 2
subclone 1
(PML-RARA)
X + 1
Y + (1 to 5)
X + 1
Y + (1 to 5)
Z1 + (1 to 2)
X + 1
Y + (1 to 5)
Z2 + (1 to 2)
(FLT3 and others)
cooperating mutations
X: age-dependent passenger mutations pre-existing in HSPC
Y: passenger mutations gained between initiating and cooperating mutations
Z: passenger mutations gained during progression to subclones
Figure 7. Integrated Model for the Origin of
Driver and Passenger Mutations during
AML Evolution
Hematopoietic stem/progenitor cells (HSPCs,
shown in green) accumulate random, benign
background mutations as a function of age. ‘‘X’’
represents these background mutations in the
HSPCs, and may range from 100 to 1,000
events, depending on age. The initiatingmutations
are different for M1 AML cases and M3 AML ca-
ses. Because the initiating event provides an
advantage for the affected cell, clonal expansion
ensues, so that all of the preexisting mutations in
that cell are ‘‘captured’’ by cloning. Each cooper-
ating mutation gives the expanding clone an
additional advantage; our data suggest that 1–5
events contribute to progression in most cases of
AML. Each cooperating mutation is expected to
capture all mutations that occurred between the
initiating event and the progression event (desig-
nated as ‘‘Y’’ in the yellow cell). Although this
number is unknown, the analysis of clonal
progression of secondary AML (Walter et al., 2012)
suggests that each cooperatingmutationmay capture dozens to hundreds ofmutations. The ‘‘founding’’ AML clone is designated in red. Subclones arise from the
founding AML clone by acquiring a small number of additional mutations that confer an advantage to that cell, along with any additional background mutations
that may have occurred in the interim (represented as ‘‘Z’’). In this study, the average number of mutations captured in subclones was 40 (range 6–110).internal tandem duplications are known to cooperate with other
initiating events in mice to produce disease progression, but do
not initiate leukemia on their own (Kelly et al., 2002; Li et al., 2008;
Sallmyr et al., 2008). Although several groups have suggested
that an activated tyrosine kinase may be an essential feature of
all AML cases (Gilliland, 2002; Ishikawa et al., 2009; Pedersen-
Bjergaard et al., 2008; Zheng et al., 2009), we identified muta-
tions in alternative tyrosine kinase genes in only 1 of the 13
completely sequenced genomes that lacked a FLT3 mutation
(AML10, which contained both ABL1 P937L and DDR2 M291I).
In the entire set of 108 cases, we observed mutations in tyrosine
kinase genes in only 5 of the 69 genomes that lacked a FLT3
mutation (these four additional cases had somatic variants in
KIT D816V and D816Y, JAK2 V617F, and DDR2 G222R). We
had previously addressed this possibility by sequencing the ex-
pressed tyrosine kinases in AML cases (Tomasson et al., 2008);
however, that study was limited by the fact that only targeted
gene sequencing was performed. Here, where whole genomes
were sequenced, we are more confident that a second mutated
tyrosine kinase gene is not required for most cases of AML.
However, it is possible that mutations in protein phosphatases
and G protein receptor/modulators might substitute for kinase
mutations in some cases (Figure 6).
We identified recurring mutations in the genes that encode all
four members of the cohesin complex (STAG2, SMC3, RAD21,
and SMC1A), a set of proteins that assemble into a ring structure
that encircles sister chromatids during metaphase, maintaining
their polarity during mitosis (Carretero et al., 2010; Millau and
Gaudreau, 2011). The cohesin complex mutations occurred in
10% of non-M3 AML cases and co-occurred with NPM1,
DNMT3A, TET2, or RUNX1 mutations in 17/19 cases. Eleven of
these cohesin mutations were predicted to cause loss-of-func-
tion for the affected gene; STAG2 and SMC1A are both on the
X chromosome, and null mutations in these genes are predictedto create complete protein deficiency for the three male patients
with these mutations. All of the mutations were mutually exclu-
sive of one another, suggesting that an alteration of only one
component of the complex may be sufficient to disrupt or alter
the entire complex. Recently, loss-of-function mutations in the
STAG2 gene were shown to be associated with aneuploidy in
cancer cell lines derived from solid tumors (Solomon et al.,
2011); however, only 1 of the 19 AML genomes with cohesin
complex mutations was aneuploid. Although we do not yet
understand the mechanisms by which these mutations may
contribute to AML pathogenesis, the discovery of recurrent
mutations in the genes encoding this important structure repre-
sents yet another pathway that is undoubtedly relevant for this
disease.
Although we have focused this report on recurrently mutated
genes, we have also identified 15 recurrently mutated nongenic
regions (e.g., mutations occur within 100 base pairs of one
another) within these 24 completely sequenced genomes. We
previously reported one identical mutation in two AML genomes,
falling in a conserved but unannotated portion of the genome
(Mardis et al., 2009). None of the 15 recurrent mutations identi-
fied here was associated with altered expression of its nearest
neighbor gene, and none occurred within 10,000 base pairs of
an annotated, untranslated RNA (data not shown). As additional
AML genomes are sequenced, the identification of significantly
mutated regions may suggest functional properties for these
unannotated parts of the genome (e.g., cryptic genes or tran-
scribed regions, or regulatory domains).
In summary, we have been able to provide important insights
into the origin and evolution of AML mutations with whole-
genome sequencing. Although many AML mutations have
been discovered by sequencing more limited parts of the
genome, candidate gene sequencing and/or exome sequencing
cannot provide enough information to confidently predict the fullCell 150, 264–278, July 20, 2012 ª2012 Elsevier Inc. 275
spectrum of mutations required for disease in an individual
patient or to determine the global genomic character of a
disease. Our data suggest that most of the somatic events in
AML genomes appear to be random, preexisting, background
mutations in the hematopoietic cell that acquired the key initi-
ating mutation. This event ‘‘captures’’ the mutational history of
this cell as it evolves to become the founding clone at presenta-
tion (we have recently reported a similar phenomenon when
fibroblasts are cloned via reprogramming to become induced
pluripotent stem cells [Young et al., 2012]). Only a tiny fraction
of the total mutations in each AML genome are therefore likely
to be relevant for pathogenesis, for disease classification, and
for targeted therapy. The comprehensive analysis of AML
genomes, although technically complex, has therefore sug-
gested that AML is not a disease caused by hundreds of muta-
tions, but only a few. These data may have implications for the
origins of mutations in other cancer types as well.
EXPERIMENTAL PROCEDURES
Whole-Genome Sequencing and Somatic Mutation Discovery
Whole-genome sequence data were generated by using Illumina GA and Illu-
minaGA IIx instruments (Ley et al., 2008;Mardis et al., 2009). Paired-end reads
50100 bp in length were aligned to NCBI 36 by usingMaq (v0.6.8 or v0.7.1) or
BWA (v0.5.5). Target haploid reference coverage was a minimum of 253 for
tumor and 203 for normal. Sample specific variants were called by using
MAQ (v0.6.8) or Samtools (r320, r453, or r599). Somatic SNVs were identified
by using SomaticSniper as previously described (Ding et al., 2012; Larson
et al., 2012). Somatic indels were detected as previously described (Ding
et al., 2012). We used Pindel in both tumor and normal and selected only tier
1 Pindel predictions regardless of filtering (could be germline or somatic) for
validation.
Somatic structural variants were identified as previously described by using
BreakDancer; structural variant predictions were not filtered based on assem-
bled sequence data from breakpoint flanking regions (Chen et al., 2009; Ding
et al., 2012). Further detail provided in Extended Experimental Procedures.
All sequence variants for the AML tumor samples from 24 cases have been
submitted to dbGaP (accession number phs000159.v3.p2).
Capture Validation and Analysis
Capture validation and analysis were performed as previously described (Ding
et al., 2012).
Mutation Cluster Analysis
Tumor clonality estimates were determined as described previously (Ding
et al., 2012). Briefly, supporting readcounts from custom capture validation
data for somatic mutations in regions of diploid copy number (2N) with
a minimum reference coverage >1003 were input into a custom R function
that drew a kernel density estimate (KDE) plot and estimated the number
and relative composition of clones in these tumors.
Extension Sequencing and Analysis
Nimblegen Liquid phase custom capture reagents were used to extend puta-
tive variant calls from the initial M1/M3 discovery data. These variants were
extended on an additional set of samples including 53 M1 and 31 M3 cases.
The target regions included 522 genes, 9 noncoding regions that had
mutations in more than one discovery sample, and 24 identity SNP sites,
and additional genes with ambiguous mutations. This final design space
was 4.6 Mb. DNA Libraries were constructed by using ligation of Illumina
adaptors to sheared whole-genome amplified DNA. A Solid Phase Reversible
Immobilization (SPRI) bead cleanup procedure was conducted to select size
fractions between 300 and 500 bp. Hybridizations were performed by using
a customized version of the Nimblegen EZ exome protocol. Barcoding
adaptors were used to enable postcapture multiplexing of 15 samples per276 Cell 150, 264–278, July 20, 2012 ª2012 Elsevier Inc.lane on the sequencing instrument. qPCR was used to determine the quantity
of captured library necessary for loading on a single lane of an Illumina Hi-Seq
2000 (2 3 100 bp) PE sequences in order to produce 2 Gbp of sequence/
sample.
Differential Mutation Frequency Analysis across Subtypes
RNA expression analysis of AML cases and flow sorted normal bone marrow
was performed with Affymetrix U133 Plus2 arrays and has been previously
published; Geo accession number GSE12662 (Payton et al., 2009).
RNA-seq-Based Expression Analysis
RNA-seq data for 155 TCGAAML tumor samples consisting of of 50 bp paired-
end reads, were extracted from BAM into FASTQ format by using Picard 1.31
(http://picard.sourceforge.net/) and subsequently aligned by using the Tophat
1.1.4 release (Trapnell et al., 2009). Cufflinks 0.9.2 (Trapnell et al., 2010) was
used to estimate expression levels for all known UCSC genes and transcript
isoforms. The resulting transcript abundance estimates are expressed in
fragments per kilobase of exon per million fragments mapped (FPKM), as
proposed by Mortazavi et al. (Mortazavi et al., 2008).
Exome Sequencing of Normal Volunteer Samples
Flow sorted CD34+ CD38 lineage cells were expanded on AFT024 stromal
cells. DNA from individual colonies was prepared, captured with Agilent Sure-
Select Human All Exon v2 kit, and sequenced by using similar methods as we
have published (Ding et al., 2012; Mardis et al., 2009; Welch et al., 2011b).
Experimental details are described in Extended Experimental Procedures.
Statistical Analysis
Students t test, Wilcoxon comparison, ANOVA, log-rank, and hypergeometric
distributionswere used to compare results from twocohorts (Prism,GraphPad,
La Jolla, California, and Excel, Microsoft, Seattle, Washington). The expected
Poisson distribution was generated by using WinPepi (Abramson, 2011).
ACCESSION NUMBERS
The database of Genotypes and Phenotypes (dbGaP) accession number for
the AML tumor sequence variants is phs000159.v3.p2.
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Supplemental Information includes Extended Experimental Procedures,
eight figures, and eight tables and can be found with this article online at
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